08.05.2013 - Belgian single chain camelidae antibody producer Ablynx has started development of an anti-IgE nanobody, code-named ALV-0962.
The Ghent-based company announced the compound will enter clinical development after Q2/2014. Ablynx believes its treatment of severe allergic asthma can outcompete Roche’s /Novartis’ marketed allergic asthma antibody Xolair (omalizumab) due to its "unique" dual mode of action. The company suggested the preclinical compound could displace receptor-bound IgE as well as binding free IgE molecules.
Due to its mode of action, Ablynx believes that ALX-0962 could address a wider patient population, including those currently not eligible to be treated with omalizumab (Xolair®). Currently, many allergic asthma treatments are in clinical development including Phase II compounds from Swedish Resistentia Pharmaceuticals AB, Takeda, Actelion or Cytos Biotechnology (CYT003-QbG10).
IgE is a key mediator in initiating an allergic reaction upon allergen exposure. IgE is a clinically and commercially validated mechanism to treat allergic asthma. Omalizumab currently is the only anti-IgE biologic approved for the treatment of patients with moderate to severe persistent allergic asthma, inadequately controlled with inhaled corticosteroids. Xolair® generated sales of $1.26bn in 2012.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.